Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.
In This Article:
The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese cancer immunotherapies in western countries?
Terms and Privacy Policy